Shmuel Rubinstein - Kamada Director
| KMDA Stock | ILA 1,986 54.00 2.80% |
Director
Mr. Shmuel Rubinstein was appointed Director of the Company., effective on November 30, 2017. Mr. Rubinstein served as Chief Executive Officer of Taro Pharmaceuticals from 1990 to 2010. During this time, the company grew from 10 million in revenue to over 400 million. He currently serves on the boards of multiple public and private biopharmaceutical companies, including Clal Biotechnology and Exalenz Bioscience Ltd. since 2017.
| Age | 78 |
| Tenure | 7 years |
| Phone | (972) 8 9406472 |
| Web | www.kamada.com |
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| Kinneret Savitsky | Compugen | 50 | |
| Arie Ovadia | Compugen | 67 | |
| Michal Preminger | Compugen | N/A | |
| Dov Hershberg | Compugen | 74 | |
| Sanford Zweifach | Compugen | 60 | |
| Ruth Arnon | Compugen | 86 | |
| Gilead Halevy | Compugen | 51 | |
| Yair Aharonowitz | Compugen | 73 | |
| Eran Perry | Compugen | N/A | |
| JeanPierre Bizzari | Compugen | 64 | |
| Joshua Shemer | Compugen | 63 | |
Management Performance
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, Vice President - Inhalation programs & IP | ||
| Itzhak Krinsky, Director | ||
| Lilach Topilsky, Chairman of the Board | ||
| Ari Shamiss, Director | ||
| Barak Bashari, Vice President - Operations | ||
| Eran Schenker, Vice President - Medical Director | ||
| Tuvia Shoham, Independent Director | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, VP Sales | ||
| Michal Stein, Vice President and Medical Director for Immunology | ||
| Ariella Raban, VP HR | ||
| Shani Dotan, Vice President of Human Resources | ||
| Liliana Bar, VP of RandD | ||
| Yael Brenner, Vice President - Quality | ||
| Abraham Havron, Independent Director | ||
| Asaf Frumerman, Director | ||
| Ruth Wolfson, Senior Vice President - Scientific Affairs | ||
| Shmuel Rubinstein, Director | ||
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
| Jon Knight, VP Operations | ||
| Michael Berelowitz, Director | ||
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
| Leon Recanati, Chairman of the Board | ||
| Gil Efron, CFO, Principal Accounting Officer and Deputy CEO | ||
| Jonathan Hahn, Director | ||
| Eran Schenkar, Vice President - Medical Director | ||
| Gwen Melincoff, Director | ||
| Chaime Orlev, Chief Financial Officer | ||
| Michal Ayalon, Vice President - Research & Development | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Executive Officer | ||
| Estery GilozRan, Independent Director | ||
| Reuven Behar, Director | ||
| Eitan Kyiet, Vice President - Business Development | ||
| Ziv Kop, Director |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 636.38 M | |||
| Shares Outstanding | 44.8 M | |||
| Shares Owned By Insiders | 18.50 % | |||
| Shares Owned By Institutions | 32.04 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 5.37 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kamada in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kamada's short interest history, or implied volatility extrapolated from Kamada options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Kamada Stock analysis
When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |